Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Pastimes : Clown-Free Zone... sorry, no clowns allowed -- Ignore unavailable to you. Want to Upgrade?

To: NOW who wrote (163484)	5/2/2002 6:44:28 PM
From: reaper	Read Replies (1) \| Respond to of 436258

I'm sorry, I tried very hard to temper my comments and not sound "gloomy." But, to quote from the press release: (i) 28 percent achieved a 75 percent or greater improvement of their psoriasis. Fifty-six percent of patients achieved 50 percent improvement in their disease. only 28% of patients achieving 75% or greater improvement in their psoriasis i would personally argue is not a high percentage. and again, I THINK that the bar for a drug being efficacious is set a little higher for non-life-threatening diseases (ii) remissions lasted an average of 10 months and as long as 18 months, Dr. Lebwohl said. "This is a truly remittive therapy where the benefit seems to be long lasting," this sounds "chronic" to me. you take the drug (injections) for twelve weeks (3 months). on average you are in remission for 10 months. presumably, then, you have to go back on the drug again since your psoriasis has come back. so its 3 months on, 7 months off, 3 months on, 7 months off, bascially "forever". this is why I think the FDA MAY want more longer-term safety data. That's my two cents, which is about all its worth. I guess we'll see in 3 weeks. Cheers